P. Pancheri, S. Bonaccorso, P. Maselli, G.D. Kotzalidis - Vol. 5, Giugno 1999, num.2
Testo Immagini Bibliografia Summary Riassunto Indice
Effetti attivanti vs. effetti
inibenti dei farmaci antidepressivi
Activating vs. sedative effects of
antidepressant drugs
1 Agnoli A, De Gregorio M, Dionisio A.
Trazodone, a review of clinical literature and personal experience.
Psychopathology 1984;17(Suppl. 2):88-103.
2 Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P,
e Coll.
Double-blind study of the efficacy and safety of sertraline versus fluoxetine
in major depression.
International Clinical Psychopharmacology 1993;8:197-202.
3 Alevizos B, Christodoulou GN, Ioannidis C, Voulgari A, Mantidis A, Spiliadis
C.
The efficacy of amineptine in the treatment of depressive patients with
irritable bowel syndrome.
Clinical Neuropharmacology 1989;12(Suppl. 2):S66-S76.
4 Amore M, Bellini M, Berardi D, Berlinzani L, Cervino G, Cremonini A, e
Coll.
Double-blind comparison of fluvoxamine and imipramine in depressed patients.
Current Therapeutic Research 1989;46:815-820.
5 Ansseau M, Darimont P, Lecoq A, De Nayer A, Evrard J-L, Krémer P, e Coll.
Controlled comparison of nefazodone and amitriptyline in major depressive
inpatients.
Psychopharmacology 1994;115:254-260.
6 Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, e Coll.
A multicenter double-blind comparison of nefazodone and paroxetine in the
treatment of outpatients with moderate-to-severe depression.
Journal of Clinical Psychiatry 1996;57(Suppl. 2):46-52.
7 Baldwin D, Hawley C, Szabadi E, Burgess J, Thomson J, Bullock R, e Coll.
Reboxetine in the treatment of depression: Early clinical experience in
the UK.
International Journal of Psychiatry in Clinical Practice 1998;2:195-201.
8 Beasley CM Jr, Sayler ME, Potvin JH.
Fluoxetine versus amitriptyline in the treatment of major depression: a
multicenter trial.
International Clinical Psychopharmacology 1993;8:143-149.
9 Beaumont G, Gringas M, Hobbs FRD, Drury VWM, Freeling P, Tylee A, e Coll.
A randomized, double blind, multi-centre parallel-group study comparing
the tolerability and efficacy of moclobemide and dothiepin hydrochloride in
depressed patients in general practice.
International Clinical Psychopharmacology 1993;7:159-165.
10 Bennie EH, Mullin JM, Martindale JJ.
A double-blind multicenter trial comparing sertraline and fluoxetine in
outpatients with major depression.
Journal of Clinical Psychiatry 1995;56:229-237.
11 Berzewski H, Van Moffaert M, Gagiano CA.
Efficacy and tolerability of reboxetine compared with imipramine in a double-blind
study in patients suffering from major depressive episodes.
European Neuropsychopharmacology 1997;7(Suppl. 1):S37-S47.
12 Bignamini A, Rapisarda V.
A double-blind multicentre study of paroxetine and amitriptyline in depressed
outpatients.
International Clinical Psychopharmacology 1992;6(Suppl. 4):37-41.
13 Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo, M.
A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained
bipolar depressives.
Acta Psychiatrica Scandinavica 1993;88:434-439.
14 Bocksberger JP, Gachoud JP, Richard J, Dick P.
Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients
with a severe depressive episode.
European Psychiatry 1993;8:319-324.
15 Bougerol T, Uchida C, Gachoud J-P, Köhler M, Mikkelsen H.
Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive
disorder (DSM III).
Psychopharmacology 1992;106(Suppl.):S102-S108.
16 Boulos C, Kutcher S, Gardner D.
An open naturalistic trial of fluoxetine in adolescents and young adults
with treatment-resistant major depression.
Journal of Child and Adolescent Psychopharmacology 1992;2:103-111.
17 Brasseur R, van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, Bartholome
F.
A Belgian multicentre study of fluvoxamine in depressive outpatients.
Acta Psychiatrica Belgica 1985;85:636-643.
18 Bremner JD.
A double-blind comparison of Org 3770, amitriptyline, and placebo in major
depression.
Journal of Clinical Psychiatry 1995;56:519-525.
19 Byerley WF, Reimherr FW, Wood DR, Grosser BI.
Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of
outpatients with major depresion.
Jounal of Clinical Psychopharmacology 1988;8:112-115.
20 Carman JS, Ahdieh H, Wyatt-Knowles E, Warga E, Panagides J.
A controlled study of mianserin in moderately to severely depressed outpatients.
Psychopharmacology Bulletin 1991;27:135-139.
21 Claghorn JL.
The safety and efficacy of paroxetine compared with placebo in a double
blind trial of depressed outpatients.
Journal of Clinical Psychiatry 1992;53(Suppl 2):33-35.
22 Claghorn JL, Feighner JP.
A double-blind comparison of paroxetine with imipramine in the long-term
treatment of depression.
Journal of Clinical Psychopharmacology 1995;15(Suppl. 2):23S-27S.
23 Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC.
Paroxetine versus placebo: A double-blind comparison in depressed patients.
Journal of Clinical Psychiatry 1992;53:434-438.
24 Clerc GE, Ruimy P, Verdeau-Paillès J.
A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized
for major depression and melancholia.
International Clinical Psychopharmacology 1994;9:139-143.
25 Cohn JB, Wilcox CS.
Paroxetine in major depression: A double-blind trial with imipramine and
placebo.
Journal of Clinical Psychiatry 1992;53 (Suppl.):52-56.
26 Conti L, Dell’Osso L, Re F, Musetti L, Cassano GB.
Fluvoxamine maleate: double-blind clinical trial vs placebo in hospitalized
depressed patients.
Current Therapeutic Rersearch 1988;43:468-480.
27 Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL.
Fluoxetine treatment of children and adults with autistic disorder and
mental retardation.
Journal of the American Academy of Child and Adolescent Psychiatry 1992;31:739-745.
28 Corne SJ, Hall JR.
A double-blind comparative study of fluoxetine and dothiepin in the treatment
of depression in general practice.
International Journal of Psychopharmacology 1989;4:245-254.
29 Del Zompo, M, Bernardi F, Burrai C, Bocchetta A.
A double-blind study of minaprine versus amitriptyline in major depression.
Neuropsychobiology 1990-91;24:79-83.
30 DeVane CL, Sallee FR.
Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology:
A review of published experience.
Journal of Clinical Psychiatry 1996;57:55-66.
31 Dick P, Ferrero E.
A double-blind comparative study of the clinical efficacy of fluvoxamine and
chlorimipramine. British Journal of Clinical Pharmacology 1983;15(Suppl.):419S-425S.
32 Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM.
A double-blind placebo-controlled study of fluvoxamine and imipramine in
depression.
Journal of Clinical Psychiatry 1985;46:84-87.
33 Doogan DP, Caillard V.
Sertraline in the prevention of depression.
British Journal of Psychiatry 1992;160:217-222.
34 Dornseif B.E., Dunlop S.R., Potvin J.H., Wernike J.F.
Effect of low dose fluoxetine therapy.
Psychopharmacology bullettin 1989 25;1 71-79.
35 Dowling B Webb MGT, Malpin CM, Sangiwa MGH.
Fluoxetine: A comparative study with dothiepin.
Irish Journal of Psychiatry 1990;11:3-7.
36 Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT.
A comparison of paroxetine and placebo in depressed outpatients.
Acta Psychiatrica Scandinavica 1993;87:302-305.
37 Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, e Coll.
A comparison of paroxetine, imipramine and placebo in depressed outpatients.
British Journal of Psychiatry 1991;159:394-398.
38 Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, e Coll.
Two combined, multicenter double-blind studies of paroxetine and doxepin
in geriatric patients with major depression.
Journal of Clinical Psychiatry 1992;53 (2, Suppl.):57-60.
39 Eberhard G, von Knorring L, Nilsson HL, Sundequist U, Björling G, Linder
H, e Coll
A double-blind randomized study of clomipramine versus maprotiline in patients
with idiopathic pain syndromes.
Neuropsychobiology 1988;19:25-34.
40 Edwards JG, Goldie A.
Placebo-controlled trial of paroxetine in depressive illness.
Human Psychopharmacology 1993;8:203-209.
41 Entsuah R, Upton GV, Rudolph R.
Efficacy of venlafaxine treatment in depressed patients with psychomotor
retardation or agitation: A meta-analysis.
Human Psychopharmacology 1995;10:195-200.
42 Fabre LF.
A 6-week, double-blind trial of paroxetine, imipramine, and placebo in
depressed outpatients.
Journal of Clinical Psychiatry 1992;53 (Suppl):40-43.
43 Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, e Coll.
Sertraline safety and efficacy in major depression: A double-blind fixed-dose
comparison with placebo.
Biological Psychiatry 1995;38:592-602.
44 Falk WE, Rosenbaum JE, Otto MW, Zusky PM, Weilburg JB, Nixon RA.
Fluoxetine versus trazodone in depressed geriatric patients.
Journal of Geriatric Psychiatry and Neurology 1989;2:208-214.
45 Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS.
Nefazodone versus sertraline in outpatients with major depression: focus
on efficacy, tolerability, and effects on sexual function and satisfaction.
Journal of Clinical Psychiatry 1996;57(Suppl. 2):53-62.
46 Feighner JP.
A comparative trial of fluoxetine and amitriptyline in patients with major
depressive disorder.
Journal of Clinical Psychiatry 1985;46:369-372.
47 Feighner JP.
The role of venlafaxine in rational antidepressant therapy.
Journal of Clinical Psychiatry 1994;55(Suppl. A): 62-68.
48 Feighner JP.
A double-blind imipramine- and placebo-controlled study of paroxetine in
depressed outpatients.
Abstract presented at CINP, Munich, August 1988.
49 Ferguson JM, Mendels J, Manowitz NR (for the Prothiaden Collaborative
Study Group).
Dothiepin versus doxepin in major depression: results of a multicenter,
placebo-controlled trial.
Journal of Clinical Psychiatry 1994;55:258-263.
50 Ferrari G, Berardi D, Berlinzani L, Bellini M, Cervino G, Innamorati A.
A double-blind comparative trial with viloxazine and amitriprtyline in
inpatients with major non-psychotic depressive disorders.
Current Therapeutic Research 1987;42:1088-1095.
51 Fluoxetine Bulimia Nervosa Collaborative Study Group.
Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled,
double-blind trial.
Archives of General Psychiatry 1992;49:139-147.
52 Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, e Coll.
A double-blind comparison of nefazodone, imipramine, and placebo in major
depression.
Journal of Clinical Psychiatry 1994;55:234-241.
53 Franchini L, Gasperini M, Smeraldi E.
A 24-month follow-up study of unipolar subjects: a comparison between lithium
and fluvoxamine.
Journal of Affective Disorders 1994;32:225-231.
54 Freeman CPL, Trimble MR, Deakin JFW, Stokes TM, Ashford JJ.
Fluvoxamine versus clomipramine in the treatment of obsessive compulsive
disorder: A multicenter, randomized, double-blind, parallel group comparison.
Journal of Clinical Psychiatry 1994;55:301-305.
55 Freeman EW, Rickels K, Sondheimer SJ, Witmaack FM.
Sertraline versus desipramine in the treatment of premenstrual syndrome:
An open-label trial.
Journal of Clinical Psychiatry 1996;57:7-11.
56 Gagiano CA, Fourie J, Müller FGM.
The therapeutic efficacy and side effect profile of paroxetine compared
to amitriptyline.
Abstract presented at The Paroxetine Symposium, October 1988, Roma.
57 Gagiano CA, Müller FGM, Berk M, Joubert PM, Brown RGCW, Schall R.
Moclobemide twice daily in the treatment of major depressive episode: A
double-blind, multicenter comparison with different three times daily dosage
schedules.
Journal of Clinical Psychopharmacology 1995;15(Suppl. 2):4S-9S.
58 Gelenberg AJ, Wojcik JD, Lydiard RB, McCormick MGF, Falk WE, Hicks RH,
Curren FC, Cohen BM.
Double-blind comparison of amoxapine and imipramine in the treatment of
depressed patients.
Journal of Clinical Psychiatry 1984;45:54-59.
59 Gonella G, Baignoli G, Ecari U.
Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind
controlled study.
Current Medical Research and Opinion 1990;12:177-184.
60 Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL.
A double-blind comparison of clomipramine, desipramine, and placebo in
the treatment of autistic disorder.
Archives of General Psychiatry 1993;50:441-447.
61 Gründer G, Wetzel H, Hammes E, Benkert O.
Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression.
Psychopharmcology 1993;111:123-126.
62 Guelfi JD, Payan C, Fermanian J, Pedarriosse A-M, Manfredi R.
Moclobemide versus clomipramine in endogenous depression. A double-blind
randomised clinical trial.
British Journal of Psychiatry 1992;160:519-524.
63 Heinze G, Rossel L, Gabelic I, Galeano-Munoz J, Stabl M, Allen SR.
Double-blind comparison of moclobemide and tranylcypromine in depression.
Pharmacopsychiatry 1993;26:240-245.
64 Hopfer Petersen HE, Lyby K, Elsborg L, Skovlund E.
Side effect profile and safety of citalopram.
Poster presented at XVIth CINP Congress, Munich 1988.
65 Hutchinson DR, Tong S, Moon CAL, Vince M, Clarke A.
A double blind study in general practice to compare the efficacy and tolerability
of paroxetine and amitriptyline in depressed elderly patients.
British Journal of Clinical Research 1991;2:43-57.
66 Invernizzi G, Aguglia E, Bertolino A, Casacchia M, Ciani N, Marchesi GF,
Nardini M, Rapisarda V.
The efficacy and safety of tianeptine in the treatment of depressive disorder:
results of a controlled double-blind multicentre study vs. amitriptyline.
Neuropsychobiology 1994;30:85-93.
67 Jain U, Birmaher B, Garcia M.
Fluoxetine in children and adolescents with mood disorders: A chart review
of efficacy and adverse effects.
Journal of Child and Adolescent Psychopharmacology 1992;2:259-265.
68 Jaskari MO, Ahlfors UG, Ginman L, Lydekcne K, Tienari P.
Three double-blind comparatie trials of mianserin (Org GB 94) and amitriptyline
in the treatment of depressive illness.
Pharmakopsychiatrie und Neuro-psychopharmakologie 1977;10:101-103.
69 Judge R, Burnham D, Steiner M, Gergel I, Oakes R, Bailer D, Wheadon D.
Paroxetine long-term safety and efficacy in panic disorder and prevention
of relapse: a double-blind study.
Congress Poster-SmithKline Beecham.
70 Jukes AM.
Maprotiline (Ludiomil): Side effects and overdosage.
Journal of International Medical Research 1975;3(Suppl. 2) 126-145.
71 Khan A, Fabre LF, Rudolph R.
Venlafaxine in depressed outpatients.
Psychopharmacology Bulletin 1991;27:141-144.
72 Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R.
Venlafaxine in depressed geriatric outpatients: an open-label clinical
study.
Journal of the American Geriatric Society 1995, in corso di stampa.
73 Kiev A.
A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
Journal of Clinical Psychiatry 1992;53(Suppl.):27-29.
74 Klok CJ, Brower GJ, van Praag HM, Doogan D.
Fluvoxamine and clomipramine in depressed patients.
Acta Psychiatrica Scandinavica 1981;64:1-11.
75 Kreider MS, Bushnell WD, Oakes R, Wheadon DE.
A double-blind, randomized study to provide safety information on switching
fluoxetine-treated patients to paroxetine without an interveneing washout
period.
Journal of Clinical Psychiatry 1995;56:142-145.
76 Kuha S, Mehtonen O-P, Henttonen A, Naarala M.
The efficacy of fluoxetine versus maprotiline in depressed patients and
by dose.
Nordisk Psykiatrisk Tidsskrift 1991;45:109-117.
77 Kuhs H, Rudolf GAE.
A double-blind study of the comparative antidepressant effect of paroxetine
and amitriptyline.
Abstract presented at The Paroxetine Symposium, October 1988, Roma.
78 Lancaster SG, Gonzalez JP. Lofepramine.
A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic
efficacy in depressive illness.
Drugs 1989;37:123-140.
79 La Pia S, Giorgio D, Ciriello R, Sannino A, De Simone L, Paoletti C, e Coll.
Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine
versus mianserin in the treatment of depressive disorders in the elderly.
Current Therapeutic Research 1992;52:847-858.
80 Lapierre YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N, e Coll.
Treatment of major affective disorder with fluvoxamine.
Journal of Clinical Psychiatry 1987;48:65-68.
81 Lecrubier Y, Boyer P, Puech A, Aubin F, Rein W.
Amisulpride versus imipramine and placebo in dysthymia.
XVIII Collegium Internationale Neuro-Psychopharmacologicum, 28 giugno-2
luglio 1992, Nice-Abstracts Book.
82 Leonard HL, Lenane MC, Swedo SE, Rettew DC, Rapoport JL.
A double-blind comparison of clomipramine and desipramine treatment of
severe onychophagia (nail biting).
Archives of General Psychiatry 1991;48:821-827.
83 Leonard HL, Swedo SE, Lenane MC, Rettew DC, Cheslow DL, Hamburger SD,
Rapoport JL.
A double-blind desipramine substitution during long-term clomipramine treatment
in children and adolescents with obsessive-compulsive disorder.
Archives of General Psychiatry 1991;48:922-927.
84 Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, e Coll.
Treatment of obsessive-compulsive disorder with clomipramine and desipramine
in children and adolescents. A double-blind crossover comparison.
Archives of General Psychiatry 1989;46:1088-1092.
85 Leyman S, Mattelaer PM, Van Steenberge I, Schotte G.
Paroxetine: post-marketing experience in 4024 depressed patients in Belgium.
European Journal of Clinical Research 1995;7:287-296.
86 Lingjærde O, Jørgensen J, Støren R, Thomle S, Wendt Ræder L, Ruud LE,
e Coll.
A double-blind comparison of moclobemide and doxepin in depressed general
practice patients.
Acta Psychiatrica Scandinavica 1995;92:125-131.
87 Lonnqvist J, Sihvo S, Syvälahti E, Sintonen H, Kiviruusu O, Pitkanen H.
Moclobemide and fluoxetine in the prevention of relapses following acute
treatment of depression.
Acta Psychiatrica Scandinavica 1995;91:189-194.
88 Lonnqvist J, Sintonen H, Syvälahti E, Appelberg B, Koskinen T, Mannikko
T, e Coll.
Antidepressant efficacy and quality of life in depression: a double-blind
study with moclobemide and fluoxetine.
Acta Psychiatrica Scandinavica 1994;89:363-369.
89 Lund Laursen A, Mikkelsen PL, Rasmussen S, le Fèvre Honoré P.
Paroxetine in the treatment of depression - a randomized comparison with
amitriptyline.
Acta Psychiatrica Scandinavica 1985;71:249-255.
90 Magni G, Hackett D.
Venlafaxine: tolerance and safety.
XVIII CINP Congress, Official Satellite Symposium, June 28, 1992, Acropolis,
Nice, France, Abstracts Book .
91 March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH.
A double-blind, placebo-controlled trial of fluvoxamine versus imipramine
in outpatients with major depression.
Journal of Clinical Psychiatry 1990;51:200-202.
92 Marshall RJ.
The pharmacology of mianserin(an update.
British Journal of Clinical Pharmacology 1983;15:163S-168S.
93 McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Quitkin FM, Markowitz J.
Placebo-controlled study of mianserin in depressed outpatients.
Neuropsychobiology 1985;14:128-132.
94 Mendels J, Johnston R, Mattes J, Riesenberg R.
Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
Psychopharmacology Bulletin 1993;29:169-174.
95 Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF.
A double-blind, placebo-controlled trial of two dose ranges of nefazodone
in the treatment of depressed outpatients.
Journal of Clinical Psychiatry 1995;56(Suppl. 6):30-36.
96 Mendis N, Hanwella DRC, Weerasinghe C, Illesinghe DS, De Silva D.
A double-blind comparative study: Amineptine (Survector 100) versus imipramine.
Clinical Neuropharmacology 1989;12(Suppl. 2):S58-S65.
97 Mertens C, Pintens H.
Paroxetine in the treatment of depression. A double-blind multicenter study
versus mianserin.
Acta Psychiatrica Scandinavica 1988;77:683-688.
98 Montgomery SA.
Safety of mirtazapine: a review.
International Clinical Psychopharmacology 1995;10(Suppl. 4):37-45.
99 Montgomery S.A., Rasmussen J.G, Tanghoj P.
A 24 week study of 20 mg. citalopram, 40 mg. citalopram and placebo
in the prevention of relapse of major depression.
International Clinical Psychopharmacology 1993;8: 181-188.
100 Montgomery SA, Reimitz P-E, Zivkov M.
Mirtazapine versus amitryptiline in the long-term treatment of depression:
a double-blind placebo-controlled study.
International Clinical Psychopharmacology 1998;13:63-73.
101 Moon CAL, Jago W, Wood K, Doogan DP.
A double-blind comparison of sertraline and clomipramine in the treatment
of major depressive disorder and associated anxiety in general practice.
Journal of Psychopharmacology 1994;8:171-176.
102 Mucci M.
Reboxetine: a review of antidepressant tolerability.
Journal of Psychopharmacology 1997;11(Suppl. 4):S33-S37.
103 Mullin JM, Pandita-Gunawardena VR, Whitehead AM.
A double-blind comparison of fluvoxamine and dothiepin in the treatment
of major affective disorder.
British Journal of Clinical Practice 1988;42:51-55.
104 Murphy JE.
Mianserin in the treatment of depressive illness and anxiety states in
general practice.
British Journal of Clinical Pharmacology 1978; 5(Suppl.) 81S-85S.
105 Nair NPV, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin NMK, e Coll.
Moclobemide and nortriptyline in elderly depressed patients. A randomized,
multicentre trial against placebo.
Journal of Affective Disorders 1995;33:1-9.
106 Newborn G, Edwards R, Thomas H, Collier J, Fox K, Collins C, e Coll.
A comparison of the efficacy and tolerability of moclobemide given as a
single dose or in three divided doses per day for the treatment of patients
with a major depressive episode (DSM-III-R).
Journal of Clinical Psychopharmacology 1995;15(Suppl. 2):10S-15S.
107 Nielsen OA, Morsing I, Petersen JS, Larsen T, Møller SE, Manniche PM,
e Coll.
Paroxetine and imipramine treatment of depressive patients in a controlled
multicentre study with plasma amino acid measurements.
Acta Psychiatrica Scandinavica 1991;84:233-241.
108 Nolen WA, Haffmans PMJ, Bouvy PF, Duivenvoorden HJ.
Monoamine oxidase inhibitors in resistant major depression. A double-blind
comparison of brofaromine and tranylcypromine in patients resistant to tricyclic
antidepressants.
Journal of Affective Disorders 1993;28:189-197.
109 Nørregaard J, Volkmann H, Danneskiold-Samsøe B.
A randomized controlled trial of citalopram in the treatment of fibromyalgia.
Pain 1995;61:445-449.
110 Nyth AL, Gottfries CG, Lyby K, Smedegaard Andersen L, Gylding Sabroe
J, Kristensen M, e Coll.
A controlled multicenter clinical study of citalopram and placebo in elderly
depressed patients with and without concomitant dementia.
Acta Psychiatrica Scandinavica 1992;86:138-145.
111 Øhrberg S, Christiansen PE, Severin B, Calberg H, Nikantanan B, Borup
A, e Coll.
Paroxetine and imipramine in the treatment of depressive patients in psychiatric
practice.
Acta Psychiatrica Scandinavica 1992;86:437-444.
112 Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Søegaard
J, e Coll.
Paroxetine in the treatment of panic disorder. A randomised, double-blind,
placebo-controlled study.
British Journal of Psychiatry 1995;167:374-379.
113 Palmer KJ, Benfield P.
Fluvoxamine. An overview of its pharmacological properties and review of
its therapeutic potential in non-depressive disorders.
CNS Drugs 1994;1:57-87.
114 Patay M, Fraud JP, Werquin J.
Étude multicentrique de la minaprine en médicine générale.
Psychologie Médicale 1981;13:1275-85.
115 Pelicier Y, Shaeffer P.
A multi-centre double blind study to compare the efficacy and tolerability
of paroxetine and clomipramine in elderly patients with reactive depression.
Encéphale 1993;19:257-261.
116 Pinder RM.
Mianserin: Pharmacological and clinical correlates.
Nordisk Psykiatrisk Tidsskrift 1991;45(Suppl. 24):13-26.
117 Pinder RM, Fink M.
Mianserin.
Modern Problems of Pharmacopsychiatry 1982;18:70-101.
118 Porro V, Fiorenzoni S, Menga C, de Cristofaro A, Bertolino A.
Single-blind comparison of the efficacy of fluvoxamine versus placebo in
patients with depressive syndrome.
Current Therapeutic Research 1988;43:621-629.
119 Rabkin JG, Rabkin R, Harrison W, Wagner G.
Effect of imipramine on mood and enumerative measures of immune status
in depressive patients with HIV illness.
American Journal of Psychiatry 1994;151:516-523.
120 Rampello L, Nicoletti G, Raffaele R, Drago F.
Comparative effects of amitriptyline and amineptine in patients affected
by anxious depression.
Neuropsychobiology 1995;31:130-134.
121 Ravizza L, Maina G, Rocca P, Zinalda E, Torta R.
Mianserina ed amitriptilina nel trattamento della depressione maggiore.
Studio in doppio cieco, a lungo termine ed alto dosaggio.
XXXVII Congresso SIP, Roma 6-1/2/1989, Suppl. II, pp. 407-417, CIC
Edizioni Internazionali, Roma 1989.
122 Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, e Coll.
Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled,
multicenter comparison study in outpatients with major depression.
Journal of Clinical Psychiatry 1990;51(Suppl. B):18-27.
123 Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weisse C.
A placebo-controlled, double-blind, clinical trial of paroxetine in depressed
outpatients.
Acta Psychiatrica Scandinavica 1989;80(Suppl. 350):117-123.
124 Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weisse C.
The efficacy and safety of paroxetine compared with placebo in outpatients
with major depression.
Journal of Clinical Psychiatry 1992;53(Suppl.):30-32.
125 Rickels K, Csanalosi I, Newman H, Hurowitz A, Werblofsky J, White N.
Trazodone and amitriptyline in depressed outpatients-a controlled study. In
Trazodone, A New Broad-spectrum Antidepressant.
Amsterdam: Excerpta Medica 1980.
126 Rickels K, Schweizer E, Clary C, Fox I, Weise C.
Nefazodone and imipramine in major depression: A placebo-controlled trial.
British Journal of Psychiatry 1994;164:802-805.
127 Riddle MA, King RA, Hardin MT.
Behavioural side effects of fluoxetine in children and adolescents.
Journal of Child and Adolescent Psychopharmacology 1990;1:193-198.
128 Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, e Coll.
Double-blind, crossover trial of fluoxetine and placebo in children and
adolescents with obsessive-compulsive disorder.
Journal of the American Academy of Child and Adolescent Psychiatry 1992;31:1062-1069.
129 Rosen J, Sweet R, Pollock BG, Mulsant BH.
Nortriptyline in the hospitalized elderly: Tolerance and side effect reduction.
Psychopharmacology Bulletin 1993;29:327-331.
130 Rouillon F.
A double-blind, multicentre study comparing increased doses of paroxetine
(20-50 mg) and clomipramine (50-150 mg) in elderly patients with
major depression.
5th World Congress of Biological Psychiatry, Firenze, 28-29-giugno 1991,
Book of Abstracts PX0473.
131 Russell GFM, Niaz U, Wakeling A, Slade PD.
Comparative double-blind trial of mianserin hydrochloride (Organon GB94)
and diazepam in patients with depressive illness.
British Journal of Clinical Pharmacology 1978;5(Suppl.) 57S-65S.
132 Saletu B, Schjerve M, Grünberger J, Schanda H, Arnold OH.
Fluvoxamine – A new serotonin re-uptake inhibitor: first clinical
and psychometric experiences in depressed patients.
Journal of Neural Transmission 1977;41:17-36.
133 Samuelian JC, Tatossian A, Hackett D.
A randomised, double-blind, parallel group comparison of venlafaxine and
clomipramine in outpatients with major depression.
Clinical Neuropharmacology 1992;15(Suppl. 1, pt. B):324B.
134 Schifano F, Garbin A, Renesto V, De Dominicis MG, Trinciarelli G, Silvestri
A, e Coll.
A double-blind comparison of mianserin and maprotiline in depressed medically
ill elderly people.
Acta Psychiatrica Scandinavica 1990;81:289-294.
135 Schöne W, Ludwig M.
A double-blind study of paroxetine compared with fluoxetine in geriatric
patients with major depression.
Journal of Clinical Psychopharmacology 1993;13(Suppl. 2):34S-39S.
136 Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ.
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head twitches in
the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: modulation
by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Journal of Pharmacology and Experimental Therapeutics 1995;273:101-112.
137 Schweizer E, Feighner J, Mandos LA, Rickels K.
Comparison of venlafaxine and imipramine in the acute treatment of major
depression in outpatients.
Journal of Clinical Psychiatry 1994;55:104-108.
138 Schweizer E, Weise C, Clary C, Fox I, Rickels K.
Placebo-controlled trial of venlafaxine for the treatment of major depression.
Journal of Clinical Psychopharmacology 1991;11:233-236.
139 Shillingford JS, Hindmarch I, Clarke A, Vince MJ.
A double-blind comparison of paroxetine and dothiepin on efficacy and tolerability
in depressed community patients.
Paper presented at the Collegium Internationale Neuro-Psychopharmacologicum,
Kyoto, Japan 1990 (opera citata in Donovan S, McGrady H, Pownall R, Rees JA,
eds. The efficacy and tolerability of dothiepin and three selective serotonin
reuptake inhibitors in the treatment of major depression: a review of six
double-blind studies. Current Therapeutic Research 1993;54:275-289).
140 Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J,
e Coll.
Long-term safety and clinical acceptability of venlafaxine and imipramine
in outpatients with major depression.
Journal of Clinical Psychopharmacology 1994;14:322-329.
141 Shrivastava RK, Shrivastava SHP, Overweg N, Blumhardt CL.
A double-blind comparison of paroxetine, imipramine, and placebo in major
depression.
Journal of Clinical Psychiatry 1992;53(Suppl.):48-51.
142 Siddiqui UA, Chakravarti SK, Jesinger DK.
The tolerance and antidepressive effect of fluvoxamine as a single dose
compared to a twice daily dose.
Current Medical Research and Opinion 1985;9:681-690.
143 Sitsen JMA, Zivkov M.
Mirtazapine: clinical profile.
CNS Drugs 1995;4(Suppl. 1):39-48.
144 Smith WT, Glaudin V.
A placebo controlled trial of paroxetine in the treatment of major depression.
Journal of Clinical Psychiatry 1992;53(Suppl.):36-39.
145 South Wales Antidepressant Drug Trial Group.
A double-blind multicentre trial of fluoxetine and diothepin in major depressive
illness.
International Journal of Clinical Psychopharmacology 1988;3:75-81.
146 Stabl M, Casas A, Blajev B, Bajetta G, Zöchling R, Holsboer-Trachsler
E, e Coll.
A double-blind comparison of moclobemide and thioridazine versus moclobemide
and placebo in the treatment of refractory, severe depression.
Journal of Clinical Psychopharmacology 1995;15(Suppl. 2):41S-45S.
147 Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W.
Meta-analysis of randomized, double-blind, placebo-controlled, efficacy
and safety studies of mirtazapine versus amitriptyline in major depression.
Acta Psychiatrica Scandinavica 1997;96(Suppl. 391):22-30.
148 Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J.
Acute, subchronic and withdrawal sleep EEG changes during treatment with
paroxetine and amitriptyline: A double-blind randomized trial in major depression.
Sleep 1995;18:470-477.
149 Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, e Coll.
for the Canadian Fluoxetine/Prementrual Dysphoria Collaborative Study Group.
Fluoxetine in the treatment of premenstrual dysphoria.
New England Journal of Medicine 1995;332:1529-1534.
150 Stuppaeck CH, Geretsegger C, Whitworth AB, Schubert H, Platz T, König
P, e Coll.
A multicenter double-blind trial of paroxetine versus amitriptyline in
depressed inpatients.
Journal of Clinical Psychopharmacology 1994;14:241-246.
151 Swedo SE, Leonard HL, Rapoport JL, Lenane MC, Goldberger EL, Cheslow
DL.
A double-blind comparison of clomipramine and desipramine in the treatment
of trichotillomania (hair pulling).
New England Journal of Medicine 1989;321:497-501.
152 Tiller JWG, Johnson GFS, Burrows GD.
Moclobemide for depression: an Australian Psychiatric Practice Study.
Journal of Clinical Psychopharmacology 1995;15(Suppl. 2):31S-34S.
153 Tollefson GD, Birkett M, Koran L, Genduso L.
Continuation treatment of OCD: Double-blind and open-label experience with
fluoxetine.
Journal of Clinical Psychiatry 1994;55(Suppl.):69-76.
154 Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST.
Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction
between venlafaxine and diazepam.
Journal of Clinical Pharmacology 1995;35:410-419.
155 Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R.
Pharmacotherapy of social phobia. A controlled study with moclobemide and
phenelzine.
British Journal of Psychiatry 1992;161:353-360.
156 Volz H-P, Faltus F, Magyar I, Möller H-J.
Brofaromine in treatment-resistant depressed patients-a comparative trial
versus tranylcypromine.
Journal of Affective Disorders 1994;30:209-217.
157 Volz H-P, Heimann H, Bellaire J, Laux G, Möller H-J.
Brofaromine in non-endogenous major depressed inpatients-results of a preliminary
dose-finding trial versus tranylcypromine.
Pharmacopsychiatry 1994;27:152-158.
158 Wagner W, Zaborny BA, Gray TE.
Fluvoxamine. A review of its safety profile in worldwide studies.
International Clinical Psychopharmacology 1994;9:223-227.
159 Wakelin JS.
Fluvoxamine in the treatment of the older depressed patient: double-blind,
placebo-controlled data.
International Clinical Psychopharmacology 1986;1:21-230.
160 Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M.
Low-dose fluoxetine therapy for depression.
Psychopharmacology Bulletin 1988;24:183-188.
161 Wheatly DP, van Moffaert M, Timmerman L, Kremer CME, Mirtazapine-Fluoxetine
Group
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in
patients with moderate to severe major depressive disorder.
Journal of Clinical Psychiatry 1998;59: 306-312.
162 Wilcox CS, Cohn JB, Katz BB, Mijares CP, Guarino JJ, Panagides J, DeFrancisco
DF.
A double-blind, placebo-controlled study comparing mianserin and amitriptyline
in moderately depressed outpatients.
International Clinical Psychopharmacology 1994;9:271-279.
163 Zivkov M, de Jongh GD.
Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre
trial in hospitalized depressed patients.
Human Psychopharmacology 1995;10:173-180.
164 Shapiro AK, Morris LA.
The placebo effect in medical and psychological therapies.
In: Garfield SL, Bergin AE, eds. Handbook of Psychotherapy and Behavioral
Change: An Empirical Analysis, 2nd ed. New York: John Wiley & Sons
1978.
165 Pancheri L, Brugnoli R, Marconi PL, Pancheri P.
Il placebo come farmaco. Parte seconda. Il trattamento della depressione.
Rivista di Psichiatria 1991;26:1-11.
166 Pancheri P, Pancheri L, Kotzalidis GD, Marconi PL, Brugnoli R.
Il placebo come farmaco: Il trattamento dell’ansia.
Rivista di Psichiatria 1989;24:133-144.
167 Gaillard J-M, Nicholson AN, Pascoe PA.
Neurotransmitter systems.
In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep
Medicine, 2nd ed. Philadelphia: WB Saunders 1994.
168 Bergeron R, de Montigny C, Debonnel G.
Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate.
Naunyn-Schmiedeberg’s Archives of Pharmacology 1995;351:252-260.
169 Faherty CJ, Earley B, Leonard BE.
Behavioural effects of selective serotonin reuptake inhibitors following
direct microinjection into the left red nucleus of the rat.
Journal of Psychopharmacology 1997;11:53-58.
170 Muñoz-Acedo G, Izquierdo-Claros RM, Puebla L, Rodriguez-Martín E, Arilla
E.
Influence of fluoxetine and p-chloroamphetamine on the somatostatin receptor-adenylyl
cyclase system in the rat frontoparietal cortex.
Molecular Brain Research 1997;47:117-124.
171 Harro J, Lofberg C, Pakhla R, Matto V, Rago L, Oreland L, e Coll.
Different molecular forms of cholecystokinin and CCKB receptor binding
in the rat brain after chronic antidepressant treatment.
Naunyn-Schmiedeberg’s Archives of Pharmacology 1997;335:57-63.
172 Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R.
Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant
treatment: implications for the pharmacotherapy of depression.
Pharmacopsychiatry 1996;29:23-26.
173 Narita N, Hashimoto K, Tomitaka S, Minabe Y.
Interactions of selective serotonin reuptake inhibitors with subtypes of
sigma receptors in rat brain.
European Journal of Pharmacology 1996;307:117-119.
174 Fairweather DB, Ashford J, Hindmarch I.
Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy
volunteers.
Pharmacology, Biochemistry, and Behavior 1996;53:265-269.
175 Raoux N, Benoit O, Dantchev N, Denise P, Franc B, Allilaire J-F, e Coll.
Circadian pattern of motor activity in major depressed patients undergoing
antidepressant therapy: relationships between actigraphic measures and clinical
course.
Psychiatry Research 1994;52:85-98.